CONTINGENT PRODUCT RIGHTS

Financing services in the nature of a non-equity dilutive form of financing whereby an individual investor finances a pharmaceutical company for the company's development of medicine in exchange for rights from the pharmaceutical company to a predesignated number of dosages of the medicine developed from the utilization of the financing upon Federal Drug Administration approval of the medicine